Tags

Type your tag names separated by a space and hit enter

Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups.
Vasc Health Risk Manag. 2015; 11:71-8.VH

Abstract

BACKGROUND

The clinical EXCITE (EXperienCe of amlodIpine and valsarTan in hypErtension) study reported clinically relevant blood pressure (BP) reductions across all doses of amlodipine/valsartan (Aml/Val) and Aml/Val/hydrochlorothiazide (HCT) single-pill combinations. The study prospectively observed a multiethnic population of hypertensive patients for 26 weeks who were treated according to routine clinical practice. Here, we present the results in high-risk subgroups including the elderly, obese patients, and patients with diabetes or isolated systolic hypertension. In addition, we present a post hoc analysis as per prior antihypertensive monotherapy and dual therapy.

METHODS

Patients prescribed Aml/Val or Aml/Val/HCT were assessed in this 26±8 week, noninterventional, multicenter study across 13 countries in the Middle East and Asia. Changes in mean sitting systolic BP, mean sitting diastolic BP, and overall safety were assessed.

RESULTS

Of a total of 9,794 patients analyzed, 8,603 and 1,191 patients were prescribed Aml/Val and Aml/Val/HCT, respectively. Among these, 15.5% were elderly, 32.5% were obese, 31.3% had diabetes, and 9.8% had isolated systolic hypertension. Both Aml/Val and Aml/Val/HCT single-pill combinations, respectively, were associated with clinically relevant and significant mean sitting systolic/diastolic BP reductions across all subgroups: elderly patients (-32.2/-14.3 mmHg and -38.5/-16.5 mmHg), obese patients (-32.2/-17.9 mmHg and -38.5/-18.4 mmHg), diabetic patients (-30.3/-16.1 mmHg and -34.4/-16.6 mmHg), and patients with isolated systolic hypertension (-25.5/-4.1 mmHg and -30.2/-5.9 mmHg). Incremental BP reductions with Aml/Val or Aml/Val/HCT single-pill combinations were also observed in patients receiving prior monotherapy or dual therapy for hypertension. Overall, both Aml/Val and Aml/Val/HCT were generally well tolerated.

CONCLUSION

This large, multiethnic study supports the evidence that Aml/Val and Aml/Val/ HCT single-pill combinations are effective in diverse and clinically important subgroups of patients with hypertension.

Authors+Show Affiliations

Department of Diabetology, Lipidology and Metabolism, Alexandria Faculty of Medicine, Alexandria University, Alexandria, Egypt.Lebanese University Hospital, Beirut, Lebanon.Medical Center Manila, Manila, Philippines.Pakistan Institute of Medical Sciences, Islamabad, Pakistan.Seoul National University College of Medicine, Seoul, South Korea.Chung Shan Medical University Hospital, Taichung City, Taiwan.Novartis Pharma AG, Basel, Switzerland.Novartis Pharma AG, Basel, Switzerland.

Pub Type(s)

Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25653536

Citation

Assaad-Khalil, Samir Helmy, et al. "Real-world Effectiveness of Amlodipine/valsartan and Amlodipine/valsartan/hydrochlorothiazide in High-risk Patients and Other Subgroups." Vascular Health and Risk Management, vol. 11, 2015, pp. 71-8.
Assaad-Khalil SH, Najem R, Sison J, et al. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups. Vasc Health Risk Manag. 2015;11:71-8.
Assaad-Khalil, S. H., Najem, R., Sison, J., Kitchlew, A. R., Cho, B., Ueng, K. C., DiTommaso, S., & Shete, A. (2015). Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups. Vascular Health and Risk Management, 11, 71-8. https://doi.org/10.2147/VHRM.S76599
Assaad-Khalil SH, et al. Real-world Effectiveness of Amlodipine/valsartan and Amlodipine/valsartan/hydrochlorothiazide in High-risk Patients and Other Subgroups. Vasc Health Risk Manag. 2015;11:71-8. PubMed PMID: 25653536.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups. AU - Assaad-Khalil,Samir Helmy, AU - Najem,Robert, AU - Sison,Jorge, AU - Kitchlew,Asad Riaz, AU - Cho,Belong, AU - Ueng,Kwo-Chang, AU - DiTommaso,Shelley, AU - Shete,Abhijit, Y1 - 2015/01/21/ PY - 2015/2/6/entrez PY - 2015/2/6/pubmed PY - 2015/10/20/medline KW - amlodipine KW - hydrochlorothiazide KW - real world KW - single-pill combinations KW - valsartan SP - 71 EP - 8 JF - Vascular health and risk management JO - Vasc Health Risk Manag VL - 11 N2 - BACKGROUND: The clinical EXCITE (EXperienCe of amlodIpine and valsarTan in hypErtension) study reported clinically relevant blood pressure (BP) reductions across all doses of amlodipine/valsartan (Aml/Val) and Aml/Val/hydrochlorothiazide (HCT) single-pill combinations. The study prospectively observed a multiethnic population of hypertensive patients for 26 weeks who were treated according to routine clinical practice. Here, we present the results in high-risk subgroups including the elderly, obese patients, and patients with diabetes or isolated systolic hypertension. In addition, we present a post hoc analysis as per prior antihypertensive monotherapy and dual therapy. METHODS: Patients prescribed Aml/Val or Aml/Val/HCT were assessed in this 26±8 week, noninterventional, multicenter study across 13 countries in the Middle East and Asia. Changes in mean sitting systolic BP, mean sitting diastolic BP, and overall safety were assessed. RESULTS: Of a total of 9,794 patients analyzed, 8,603 and 1,191 patients were prescribed Aml/Val and Aml/Val/HCT, respectively. Among these, 15.5% were elderly, 32.5% were obese, 31.3% had diabetes, and 9.8% had isolated systolic hypertension. Both Aml/Val and Aml/Val/HCT single-pill combinations, respectively, were associated with clinically relevant and significant mean sitting systolic/diastolic BP reductions across all subgroups: elderly patients (-32.2/-14.3 mmHg and -38.5/-16.5 mmHg), obese patients (-32.2/-17.9 mmHg and -38.5/-18.4 mmHg), diabetic patients (-30.3/-16.1 mmHg and -34.4/-16.6 mmHg), and patients with isolated systolic hypertension (-25.5/-4.1 mmHg and -30.2/-5.9 mmHg). Incremental BP reductions with Aml/Val or Aml/Val/HCT single-pill combinations were also observed in patients receiving prior monotherapy or dual therapy for hypertension. Overall, both Aml/Val and Aml/Val/HCT were generally well tolerated. CONCLUSION: This large, multiethnic study supports the evidence that Aml/Val and Aml/Val/ HCT single-pill combinations are effective in diverse and clinically important subgroups of patients with hypertension. SN - 1178-2048 UR - https://www.unboundmedicine.com/medline/citation/25653536/Real_world_effectiveness_of_amlodipine/valsartan_and_amlodipine/valsartan/hydrochlorothiazide_in_high_risk_patients_and_other_subgroups_ L2 - https://dx.doi.org/10.2147/VHRM.S76599 DB - PRIME DP - Unbound Medicine ER -